These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16914589)

  • 1. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
    Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
    Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
    Liu W; Chen Y; Wang W; Keng P; Finkelstein J; Hu D; Liang L; Guo M; Fenton B; Okunieff P; Ding I
    Am J Clin Oncol; 2003 Aug; 26(4):S103-9. PubMed ID: 12902866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
    Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
    Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
    Ko JC; Wang LH; Jhan JY; Ciou SC; Hong JH; Lin ST; Lin YW
    Lung Cancer; 2009 Sep; 65(3):290-8. PubMed ID: 19157634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N; Li H; Su F; Li J; Ma X; Gong P
    Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.
    Sun J; Liu NB; Zhuang HQ; Zhao LJ; Yuan ZY; Wang P
    Cancer Biomark; 2017; 19(1):45-50. PubMed ID: 28282799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
    Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
    Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
    Venkatesan P; Bhutia SK; Singh AK; Das SK; Dash R; Chaudhury K; Sarkar D; Fisher PB; Mandal M
    Life Sci; 2012 Oct; 91(15-16):789-99. PubMed ID: 22922496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib enhances the radiosensitizing effect of 7-hydroxystaurosporine (UCN-01) in human lung cancer cell lines.
    Kim YM; Jeong IH; Pyo H
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e399-407. PubMed ID: 22417802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
    Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
    Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
    Dittmann KH; Mayer C; Ohneseit PA; Raju U; Andratschke NH; Milas L; Rodemann HP
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):203-12. PubMed ID: 17996386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.